Preparing your results

Our searching services are busy right now. Your search will reload in five seconds.

X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

The PHD finger of the chromatin-associated protein ING2 functions as a nuclear phosphoinositide receptor.

Cell | Jul 11, 2003

http://www.ncbi.nlm.nih.gov/pubmed/12859901

Phosphoinositides (PtdInsPs) play critical roles in cytoplasmic signal transduction pathways. However, their functions in the nucleus are unclear, as specific nuclear receptors for PtdInsPs have not been identified. Here, we show that ING2, a candidate tumor suppressor protein, is a nuclear PtdInsP receptor. ING2 contains a plant homeodomain (PHD) finger, a motif common to many chromatin-regulatory proteins. We find that the PHD fingers of ING2 and other diverse nuclear proteins bind in vitro to PtdInsPs, including the rare PtdInsP species, phosphatidylinositol 5-phosphate (PtdIns(5)P). Further, we demonstrate that the ING2 PHD finger interacts with PtdIns(5)P in vivo and provide evidence that this interaction regulates the ability of ING2 to activate p53 and p53-dependent apoptotic pathways. Together, our data identify the PHD finger as a phosphoinositide binding module and a nuclear PtdInsP receptor, and suggest that PHD-phosphoinositide interactions directly regulate nuclear responses to DNA damage.

Pubmed ID: 12859901 RIS Download

Mesh terms: 1-Phosphatidylinositol 4-Kinase | Amino Acid Sequence | Apoptosis | Base Sequence | Cell Membrane | Cell Nucleus | DNA Damage | Eukaryotic Cells | Genes, Tumor Suppressor | Homeodomain Proteins | Humans | Molecular Sequence Data | Phosphatidylinositol Phosphates | Protein Binding | Protein Structure, Tertiary | RNA Interference | Receptors, Cytoplasmic and Nuclear | Signal Transduction | Tumor Cells, Cultured | Tumor Suppressor Protein p53 | Tumor Suppressor Proteins

Publication data is provided by the National Library of Medicine ® and PubMed ®. Data is retrieved from PubMed ® on a weekly schedule. For terms and conditions see the National Library of Medicine Terms and Conditions.